- Medical news & Guidelines
- Cardiology and CTVS
- Critical Care
- Diabetes and Endocrinology
- Laboratory Medicine
- Health news
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Dadra and Nagar Haveli
- Daman and Diu
- Himachal Pradesh
- Jammu & Kashmir
- Madhya Pradesh
- Tamil Nadu
- Uttar Pradesh
- West Bengal
- Medical Education
Fully closed-loop insulin therapy safe, effective in diabetes patients requiring dialysis: Study
UK: A new study in the journal Nature Medicine has reported that fully closed-loop insulin therapy improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. Management of diabetes in this population is challenging for both patients and healthcare professionals as it poses severe complications...
UK: A new study in the journal Nature Medicine has reported that fully closed-loop insulin therapy improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis.
Management of diabetes in this population is challenging for both patients and healthcare professionals as it poses severe complications of the kidney and heart. Closed-loop systems are increasingly being applied for the management of type 1 diabetes. However, the use of this technology in people with type 2 diabetes is limited to the inpatient setting including those on hemodialysis.
Charlotte K. Boughton, Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes and Endocrine Clinic, Cambridge, UK, and colleagues, therefore, aimed to evaluate the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis.
The study was an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart ('closed-loop) with standard insulin therapy and a masked continuous glucose monitor ('control') in random order. The primary endpoint was a time in target glucose range (5.6–10.0 mmol l−1).
A total of 13 participants received closed-loop first and thirteen received control therapy first.
The results of the study were
• The proportion of time in target glucose range (5.6–10.0 mmol l−1; primary endpoint) was 52.8 ± 12.5% with closed-loop versus 37.7 ± 20.5% with control; mean difference, 15.1 percentage points.
• Mean glucose was lower with closed-loop than control (10.1 ± 1.3 versus 11.6 ± 2.8 mmol l−1). Time in hypoglycemia (<3.9 mmol l−1) was reduced with closed-loop versus control (median (IQR) 0.1 versus 0.2).
Boughton and team concluded that "Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis." They also stated that no severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation.
For further information: https://doi.org/10.1038/s41591-021-01453-z
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org.